权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tunable Nicotine DNA-Nanovaccines

可调节尼古丁 DNA 纳米疫苗

基本信息

批准号：
8225234
负责人：
YUNG CHANG
金额：
$ 17.44万
依托单位：
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-04-01 至 2014-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8225234
关键词：
Adjuvant Adult Affinity American Antibodies Antibody Affinity Antibody Formation Antigens B-Lymphocytes Binding Biological Assay CD4 Positive T Lymphocytes Cell Communication Cessation of life Chemistry Collaborations Complex DNA Dendritic Cells Development Disease Engineering Enzyme-Linked Immunosorbent Assay Epitopes Evaluation Flow Cytometry Generations Goals Haptens Health Helper-Inducer T-Lymphocyte Immunologist Immunology Individual Infectious Agent Investigation Lead Ligands Malignant Neoplasms Nanostructures Nicotine Nicotine Dependence Oligonucleotides Oncogenic Peptides Positioning Attribute Procedures Production Risk Screening procedure Smoker Smoking Space Perception Structure Structure of germinal center of lymph node T-Lymphocyte TLR9 gene Technology Testing Tobacco Translations Tumor Antigens United States Vaccines base cigarette smoking design drug of abuse immunogenicity innovation interest microbial multidisciplinary novel novel therapeutics pathogen public health relevance receptor research clinical testing response smoking cessation stoichiometry vaccine development

项目摘要

DESCRIPTION (provided by applicant): Through multidisciplinary interactions and collaborations involving immunologists, organic chemists, nanostructural chemists and neuroscientists, we will employ a bottom-up strategy to engineer nicotine hapten, T helper cell peptides and adjuvant onto self-assembling DNA nanoscaffolds in a controllable fashion to induce T-cell dependent anti-nicotine antibody responses. Robust and versatile synthesis and assembly of various antigenic components onto DNA-nanoscaffolds along with step-wise screening afford opportunities to identify "optimal combinations and configurations" of the nanovaccine for the induction of strong, anti-nicotine antibody responses, leading to production of high titer and high affinity anti-nicotine antibodies for treatment of nicotine dependence. It is conceivable that this approach can be readily extended to the development of any vaccines, including those targeting drugs of abuse, microbial pathogens and tumor antigens. Thus, the project represents a proof-of-concept investigation of a new and unconventional technology in vaccine construction. PUBLIC HEALTH RELEVANCE: We propose to develop novel DNA nanovaccines against nicotine. Through rational design and step-wise screenings, we aim to create effective nicotine vaccines to treat nicotine dependence toward a longer-term goal of reducing tobacco-related diseases.

描述（由申请人提供）：通过涉及免疫学家、有机化学家、纳米结构化学家和神经科学家的多学科互动和合作，我们将采用自下而上的策略，以可控的方式将尼古丁半抗原、T辅助细胞肽和佐剂工程化到自组装DNA纳米支架上，以诱导T细胞依赖性抗尼古丁抗体应答。将各种抗原组分稳健且通用的合成和组装到DNA-纳米支架上，沿着逐步筛选，提供了鉴定纳米疫苗的“最佳组合和构型”的机会，用于诱导强的抗尼古丁抗体应答，从而产生用于治疗尼古丁依赖的高滴度和高亲和力抗尼古丁抗体。可以想象，这种方法可以很容易地扩展到任何疫苗的开发，包括那些针对滥用药物，微生物病原体和肿瘤抗原的疫苗。因此，该项目代表了疫苗构建中新的非常规技术的概念验证调查。公共卫生相关性：我们建议开发针对尼古丁的新型DNA纳米疫苗。通过合理设计和逐步筛选，我们的目标是创造有效的尼古丁疫苗来治疗尼古丁依赖，以实现减少烟草相关疾病的长期目标。